TD Cowen analyst Ritu Baral lowered the firm’s price target on Sarepta to $97 from $175 and keeps an Outperform rating on the shares. The firm said their talks with FDA consultants and DMD patient community contacts suggest their 50% POS of Elevidys label expansion to all ambulatory points may be too low.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SRPT:
- Sarepta call volume above normal and directionally bullish
- Unusually active option classes on open November 1st
- Sarepta Stock (NASDAQ:SRPT) Plunged 37% on Disappointing Elevidys Trial Data
- Catalent designated as ‘bullish Fresh pick’ at Baird with pullback ‘overdone’
- Cantor downgrades Sarepta on uncertainties after study miss